Department of Plastic and Reconstructive Surgery, Cleft and Craniofacial Center, 364090Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
95338Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Cleft Palate Craniofac J. 2021 Jun;58(6):707-717. doi: 10.1177/1055665620962360. Epub 2020 Oct 14.
To evaluate bone regeneration in alveolar defects treated with human umbilical cord-derived mesenchymal stem cells (hUCMSCs), hydroxyapatite/chitosan/gelatin (HA/CS/Gel) scaffold, and bone morphogenic protein-2 (BMP-2) in models.
Randomized posttest-only control group design.
Animal Hospital at Bogor Agricultural Institute.
Healthy and equally treated 24 female /goats.
Animals were randomly assigned to 3 experimental group design (iliac crest alveolar bone graft/ICABG [control], HA/Cs/Gel+BMP-2 [], and HA/Cs/Gel+BMP-2+UCMSCs). Graft materials were implanted in surgically made alveolar defects.
Postoperative functional score and operating time were assessed. New bone growth, bone density, inflammatory cells recruitment, and neoangiogenesis were evaluated based on radiological and histological approach at 2 time points, week 4 and 12. Statistical analysis was done between treatment groups.
Operating time was 34% faster and functional score 94.5% more superior in HA/Cs/Gel+BMP-2+hUCMSC group. Bone growth capacity in HA/Cs/Gel+BMP-2+UCMSCs mimicked ICABG, but ICABG showed possibility of bone loss between week 4 and 12. The HA/Cs/Gel+BMP-2+UCMSCs showed early bone repopulation and unseen inflammatory cells and angiogenesis on week 12.
The HA/Cs/Gel+BMP-2+hUCMSCs were superior in enhancing new bone growth without donor site morbidity compared to ICABG. The presence of hUCMSCs in tissue-engineered alveolar bone graft (ABG), supported with paracrine activity of the resident stem cells, initiated earlier new bone repopulation, and completed faster bone regeneration. The HA/Cs/Gel scaffold seeded with UCMSCs+BMP-2 is a safe substitute of ICABG to close alveolar bone defects suitable for patients with cleft lip, alveolus, and palate.
评估人脐带间充质干细胞(hUCMSCs)、羟基磷灰石/壳聚糖/明胶(HA/CS/Gel)支架和骨形态发生蛋白-2(BMP-2)在动物模型中治疗牙槽骨缺损的骨再生情况。
随机后测试仅对照组设计。
茂物农业学院动物医院。
健康且同等治疗的 24 只雌性/山羊。
动物被随机分配到 3 个实验组设计(髂嵴牙槽骨移植/ICABG[对照组]、HA/Cs/Gel+BMP-2[实验组]和 HA/Cs/Gel+BMP-2+UCMSCs[实验组])。在手术制备的牙槽骨缺损中植入移植物材料。
评估术后功能评分和手术时间。在 2 个时间点(第 4 周和第 12 周),通过放射学和组织学方法评估新骨生长、骨密度、炎性细胞募集和新血管生成。对治疗组进行统计学分析。
HA/Cs/Gel+BMP-2+hUCMSC 组的手术时间快 34%,功能评分高 94.5%。HA/Cs/Gel+BMP-2+UCMSCs 组的骨生长能力类似于 ICABG,但 ICABG 在第 4 周到第 12 周之间存在骨丢失的可能性。在第 12 周时,HA/Cs/Gel+BMP-2+UCMSCs 组表现出早期骨再填充,未见炎症细胞和血管生成。
与 ICABG 相比,HA/Cs/Gel+BMP-2+hUCMSCs 组在增强新骨生长方面具有优势,且无供体部位发病率。组织工程化牙槽骨移植物(ABG)中 hUCMSCs 的存在,支持驻留干细胞的旁分泌活性,可更早启动新骨再填充,并更快地完成骨再生。HA/Cs/Gel 支架接种 UCMSCs+BMP-2 是 ICABG 的安全替代品,可闭合牙槽骨缺损,适用于唇裂、牙槽突裂和腭裂患者。